{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:14:21Z","timestamp":1789186461037,"version":"build-2803163510"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine is a widespread, recurrent primary headache disorder primarily characterized by severe pulsatile headache, typically on one or both sides. It is often accompanied by nausea, vomiting, and hypersensitivity to sound and light. Despite the availability of multiple drugs for migraine management, the condition often becomes chronic due to untimely or irrational drug use, significantly distressing patients and increasing the burden on families and society. Over the past two decades, numerous clinical studies on migraine have been published. This study aimed to provide a comprehensive summary of the current status and trends of migraine clinical trials through bibliometric analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used visual network tools such as CiteSpace and VOSviewer to perform a knowledge graph analysis of publications related to migraine clinical trials extracted from the WoSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study analyzed 1,129 articles published in 389 journals from 61 countries. The number of publications on migraine clinical trials has steadily increased from 2004 to 2023. The United States and Albert Einstein College of Medicine are the leading countries and institutions in this field, respectively. Richard B. Lipton is the most prolific author, making significant contributions to the research. The journal Headache has the highest number of publications and citations in this area. Keywords such as \u201cefficacy,\u201d \u201cRCT,\u201d \u201cCGRP,\u201d \u201cprophylaxis,\u201d \u201cdisability,\u201d \u201cdepression,\u201d \u201cquestionnaire,\u201d and \u201creal-world effectiveness\u201d received significant attention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identified reliable research hotspots and provided directions for clinicians. The treatment of migraine continues to be challenging. Future trends may include continued growth in migraine classification, risk factor analysis, and comorbidity studies. Research on CGRP and epigenetics will advance the progress of precision medicine in the migraine field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1430138","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:34:04Z","timestamp":1729816444000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Research trends and hotspots in clinical trials of migraine in the past 20\u2009years: bibliometric analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaoxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingzhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24108681","article-title":"Molecular research on migraine: from pathogenesis to treatment","volume":"24","author":"Tuttolomondo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","article-title":"The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies","volume":"55","author":"Marmura","year":"2015","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Jes Olesen","year":"2018","journal-title":"Cephalalgia"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","article-title":"CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond","volume":"103","author":"Russo","year":"2023","journal-title":"Physiol Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies - successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/nu14051089","article-title":"Magnesium as an important factor in the pathogenesis and treatment of Migraine-from theory to practice","volume":"14","author":"Domitrz","year":"2022","journal-title":"Nutrients"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/aogs.13309","article-title":"A simplified guide to randomized controlled trials","volume":"97","author":"Bhide","year":"2018","journal-title":"Acta Obstet Gynecol Scand"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","article-title":"Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial","volume":"63","author":"Ashina","year":"2023","journal-title":"Headache"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e28152","DOI":"10.2196\/28152","article-title":"Medical and health-related misinformation on social media: bibliometric study of the scientific literature","volume":"24","author":"Yeung","year":"2022","journal-title":"J Med Internet Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1177127","DOI":"10.3389\/fimmu.2023.1177127","article-title":"Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1177\/0333102413485658","article-title":"The International Classification of Headache Disorders, 3rd edition (beta version)","volume":"33","year":"2013","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the prevention of episodic Migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1280908","DOI":"10.3389\/fneur.2023.1280908","article-title":"A bibliometric analysis of the research hotspots and frontiers related to cell death in spinal cord injury","volume":"14","author":"He","year":"2023","journal-title":"Front Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","article-title":"Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study","volume":"21","author":"Buse","year":"2020","journal-title":"J Headache Pain"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2215499","DOI":"10.1001\/jamanetworkopen.2022.15499","article-title":"Rates of response to Atogepant for Migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial","volume":"5","author":"Lipton","year":"2022","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of Ubrogepant vs placebo on pain and the Most bothersome associated symptom in the acute treatment of Migraine: the ACHIEVE II randomized clinical trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/head.14664","article-title":"The impacts of migraine on functioning: results from two qualitative studies of people living with migraine","volume":"64","author":"Mangrum","year":"2024","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1007\/s00415-023-11880-2","article-title":"Risk factors for migraine disease progression: a narrative review for a patient-centered approach","volume":"270","author":"Lipton","year":"2023","journal-title":"J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11916-004-0064-2","article-title":"Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR project","volume":"8","author":"Dodick","year":"2004","journal-title":"Curr Pain Headache Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/0333102420970523","article-title":"Time course of efficacy of ubrogepant for the acute treatment of migraine: clinical implications","volume":"41","author":"Goadsby","year":"2021","journal-title":"Cephalalgia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(23)01683-5","article-title":"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA","volume":"402","author":"Dodick","year":"2023","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1905","DOI":"10.1212\/WNL.0000000000201031","article-title":"Efficacy of Ubrogepant in the acute treatment of Migraine with mild pain vs moderate or severe pain","volume":"99","author":"Lipton","year":"2022","journal-title":"Neurology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1142\/S0192415X10008111","article-title":"Manage migraine with acupuncture: a review of acupuncture protocols in randomized controlled trials","volume":"38","author":"Zheng","year":"2010","journal-title":"Am J Chin Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1503\/cmaj.110551","article-title":"Acupuncture for migraine prophylaxis: a randomized controlled trial","volume":"184","author":"Li","year":"2012","journal-title":"CMAJ"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2079707509","DOI":"10.1177\/03331024231214731","article-title":"The international classification of headache disorders: history and future perspectives","volume":"44","author":"Olesen","year":"2024","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2069688303","DOI":"10.1177\/03331024241233937","article-title":"International classification of headache Disorders-4 - work in Progress 1","volume":"44","author":"Goadsby","year":"2024","journal-title":"Cephalalgia"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of Migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of Erenumab for episodic Migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S1474-4422(14)70128-0","article-title":"Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study","volume":"13","author":"Dodick","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","article-title":"The arrival of anti-CGRP monoclonal antibodies in Migraine","volume":"19","author":"Cohen","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","article-title":"CGRP-targeted medication in chronic migraine - systematic review","volume":"25","author":"Oliveira","year":"2024","journal-title":"J Headache Pain"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-018-0883-x","article-title":"Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal","volume":"19","author":"Lee","year":"2018","journal-title":"J Headache Pain"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1177\/0333102419856640","article-title":"Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls","volume":"39","author":"Kamm","year":"2019","journal-title":"Cephalalgia"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0333102415625614","article-title":"Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis","volume":"37","author":"van Dongen","year":"2017","journal-title":"Cephalalgia"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1177\/03331024211040467","article-title":"Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks","volume":"42","author":"Alpuente","year":"2022","journal-title":"Cephalalgia"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-024-01772-9","article-title":"Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization","volume":"25","author":"Alpuente","year":"2024","journal-title":"J Headache Pain"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ana.26472","article-title":"Salivary CGRP and Erenumab treatment response: towards precision medicine in Migraine","volume":"92","author":"Alpuente","year":"2022","journal-title":"Ann Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-023-01655-5","article-title":"Impact of headache frequency and preventive medication failure on quality of life, functioning, and costs among individuals with migraine across several European countries: need for effective preventive treatment","volume":"24","author":"Buse","year":"2023","journal-title":"J Headache Pain"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s10194-019-1053-5","article-title":"Headaches in the emergency department -a survey of patients' characteristics, facts and needs","volume":"20","author":"Doretti","year":"2019","journal-title":"J Headache Pain"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.annemergmed.2023.05.024","article-title":"Managing and preventing Migraine in the emergency department: a review","volume":"82","author":"Cortel-LeBlanc","year":"2023","journal-title":"Ann Emerg Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/head.14659","article-title":"Rural disparities in emergency department utilization for migraine care","volume":"64","author":"Rhudy","year":"2024","journal-title":"Headache"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e1448","DOI":"10.1212\/WNL.0000000000207648","article-title":"Randomized trial comparing low- vs high-dose IV dexamethasone for patients with moderate to severe Migraine","volume":"101","author":"Friedman","year":"2023","journal-title":"Neurology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"5578","DOI":"10.1007\/s12035-023-03428-2","article-title":"Epigenetic connections of the TRPA1 Ion Channel in pain transmission and neurogenic inflammation - a therapeutic perspective in Migraine?","volume":"60","author":"Fila","year":"2023","journal-title":"Mol Neurobiol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms24119127","article-title":"The epigenetics of Migraine","volume":"24","author":"Zobdeh","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/0333102417690111","article-title":"Epigenetic DNA methylation changes associated with headache chronification: a retrospective case-control study","volume":"38","author":"Winsvold","year":"2018","journal-title":"Cephalalgia"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"100089","DOI":"10.1016\/j.ynpai.2022.100089","article-title":"Analysis of the DNA methylation pattern of the promoter region of calcitonin gene-related peptide 1 gene in patients with episodic migraine: an exploratory case-control study","volume":"11","author":"Rubino","year":"2022","journal-title":"Neurobiol Pain"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/0333102410391487","article-title":"Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia","volume":"31","author":"Park","year":"2011","journal-title":"Cephalalgia"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jcm8070928","article-title":"Hsa-miR-34a-5p and hsa-miR-375 as biomarkers for monitoring the effects of drug treatment for Migraine pain in children and adolescents: a pilot study","volume":"8","author":"Gallelli","year":"2019","journal-title":"J Clin Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s12035-015-9106-5","article-title":"Serum MicroRNA signatures in Migraineurs during attacks and in pain-free periods","volume":"53","author":"Andersen","year":"2016","journal-title":"Mol Neurobiol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.3390\/cancers14215408","article-title":"Real-world study: a powerful tool for malignant tumor research in general surgery","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41398-021-01636-9","article-title":"A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: are the results consistent with the findings of randomized controlled trials?","volume":"11","author":"Katona","year":"2021","journal-title":"Transl Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1430138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:34:06Z","timestamp":1729816446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1430138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":60,"alternative-id":["10.3389\/fneur.2024.1430138"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1430138","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"article-number":"1430138"}}